TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.

John P Leonard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.